BURLINGTON, Mass., Sept. 30, 2014 /PRNewswire/ -- Decision Resources Group finds that the markets for peripheral vascular (PV) devices in Brazil, Russia, India and China (BRIC) will see robust expansion as these economies expand and as endovascular techniques are increasingly favored over surgical procedures. Although revenues will be somewhat impeded by poor distribution of health care resources, reimbursement challenges, prolonged device approval times and demand for low-cost products, the market will ultimately see strong growth.

Other key findings from Decision Resources Group's coverage of the BRIC PV device market:

  • Surgeon training: Multinational companies will continue to open physician training centers for endovascular techniques in these countries, which will help establish brand loyalty among surgeons. Boston Scientific and Medtronic have both opened regional centers in Shanghai for this purpose.
  • Ongoing use of surgical techniques: Despite this push from manufacturers, surgical procedures will remain popular in some regions because they represent a lower cost option. Surgical procedures will also be sustained because many surgeons, such as those living in rural regions, will not have easy access to the training programs available for endovascular techniques.
  • Reduced product offerings: Limited product selection will impede market expansion. Manufacturers will face difficulties in obtaining reimbursement for premium-priced products, and adoption of these products will be further limited by the presence of low-cost alternatives sold by local companies. Nonetheless, adoption of higher-end products will rise as hospitals receive greater funding and as manufacturers increase the reach of their distribution networks, supporting overall market expansion.

Comments from Decision Resources Group Analyst Sivani Paskaradevan:

  • "Drug-eluting stents (DES) and drug-coated balloons (DCBs) for lower extremities are currently available in Brazil and Russia, although adoption has been slower in these countries than in developed markets. DES are not reimbursed in Brazil, limiting their use, while Russian physicians will use coronary DES off-label for lower-limb treatment because they are available at a lower cost. DES and DCBs will both enter the Chinese and Indian markets in 2015."
  • "International competitors often establish partnerships with domestic companies because the latter are more knowledgeable about regional markets and governments tend to favor companies with a local presence. For example, Medtronic recently reached an agreement with Chinese manufacturer LifeTech Scientific. This arrangement will enhance Medtronic's local networks and expand the company's patient base."

Additional Resources:

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO

SOURCE Decision Resources Group

Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents

View Now